Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Kathryn Wood, Emeritus Professor of Immunology at the Nuffield Department of Surgical Sciences, joins Intellia Therapeutics's team of new scientific advisors focused on cell therapy in immuno-oncology and autoimmunity.

Professor kathryn wood joins new team of scientific advisors 1

Intellia Therapeutics, a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, will work alongside these experts to drive development of their ex vivo programmes in immuno-oncology and autoimmunity. The advisors hail from prestigious international institutions and collectively have both scientific and clinical expertise in cell therapies in these areas.

Professor Wood joins the company as one of Intellia’s advisors on ex vivo cell therapy in autoimmunity.

Read the full story on the Intellia Therapeutics website.